Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults.
Although RCTs remain the best way to evaluate specific interventions, clinical trial data may not be generalizable to the broad range of patients commonly encountered in the clinical setting, as they may be limited to younger patients with good baseline characteristics.
Consequently, real-world studies can provide valuable insight into less widely studied patients, particularly older patients.
View overview page
